Enhancing antitumor immunity through checkpoint blockade as a therapeutic strategy in T-cell lymphomas.

ABSTRACT: The majority of historical therapies for managing T-cell lymphomas (TCLs) have consisted of T-cell-depleting strategies. Unfortunately, these forms of therapies can hamper the ability to mount effective antitumor immune responses. Recently, the use of checkpoint inhibitors has revolutionized the therapy of solid and hematologic malignancies. The development of immunotherapies for the management of TCL has lagged behind other malignancies given 2 central reasons: (1) the competing balance of depleting malignant T cells while simultaneously enhancing an antitumor T-cell response and (2) concern for tumor hyperprogression by blocking inhibitory signals on the surface of the malignant T cell, thereby leading to further proliferation of the malignant cells. These challenges were highlighted wit

SUBMITTER: Neuwelt A 

PROVIDER: S-EPMC7479955 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature